Pan Pacific Pharmaceuticals Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pan Pacific Pharmaceuticals Inc.
INTERVIEW: Bayer sees solid asian growth after strong year
Driven mainly by new launches and underlying economic growth, Bayer is bullish over the prospects for its Asia-Pacific pharma business, predicting continued mid-term expansion ahead of the overall market.
US/China-based MicuRx completes $25m Series B round
Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $25 million in a Series B venture capital round to fund a Phase II clinical trial in the US for its next-generation oral oxazolidinone MRX-I, which already is under evaluation in Phase II trials in China.
An Australian vote for pharma: domestic players
Australian firms continue to carve a place in their home market – some more successfully than others.
Takeover talk surrounds iNova
Speculation is continuing to swirl around the possible acquisition of the privately held Australian firm iNova Pharmaceuticals by a large pharma company, although no transaction has been confirmed.
Company Information
- Industry
-
Pharmaceuticals
- Nutraceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice